• Baricitinib for IL-6–JAK Signaling Studies

  2026-09-03

  Use Baricitinib as a controlled pharmacological probe for testing IL-6–JAK1/2 dependence in PSC-inspired epithelial–immune assays. Its low-nanomolar biochemical potency and compatibility with spatially informed workflows help separate cytokine-driven STAT3 signaling from PD-L1-associated cellular context.

• Rhodamine 123: Reading Transporter Function

  2026-09-02

  Rhodamine 123 (chloride) enables real-time analysis of cellular uptake and efflux, but its signal requires careful separation of ABCB1/MDR1 activity, OATP1A2-mediated transport, and intracellular sequestration. This guide connects assay design with mechanistic lessons from recent ABCG2 drug-resistance research.

• DNP-Induced seRNA Drives NPC Metastasis

  2026-09-02

  The 2023 study identifies a carcinogen-responsive super-enhancer RNA, seRNA-NPCm, as a regulatory driver of nasopharyngeal carcinoma metastasis. Its integrated sequencing, perturbation, animal, and patient-tissue analyses connect seRNA-NPCm to an NPM1/c-Myc/NDRG1 transcriptional axis and provide a mechanistic framework for studying enhancer-derived RNA in NPC progression.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-09-01

  Hao et al. developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal–organic framework nanoparticle that combines near-infrared photothermal therapy with PD-1/PD-L1 checkpoint inhibition. The study shows how stimulus-responsive chemical assembly can coordinate tumor-cell ablation, dendritic-cell maturation, and immune activation in a melanoma-oriented therapeutic platform.

• EHEC Delays Danazol-Induced Puberty in Rats

  2026-08-31

  The 2025 reference study evaluates an Eclipta prostrata–Hordeum vulgare extract complex (EHEC) in danazol- and high-fat diet-induced rat models of precocious puberty. EHEC delayed vaginal opening, moderated ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation without changing body weight, supporting further investigation of botanical modulation of the hypothalamic–pituitary–gonadal axis.

• Bay 11-7085: NF-κB Activation Workflow

  2026-08-31

  Bay 11-7085 provides a practical pharmacologic way to connect TNFα-driven NF-κB signaling with inflammation, cell-cycle arrest, and apoptosis. This workflow translates ER-stress findings from subarachnoid hemorrhage research into controlled cellular assays while highlighting concentration, timing, and specificity safeguards.

• Belinostat (PXD101): Reliable Cell Assays

  2026-08-30

  Learn how Belinostat (PXD101), SKU A4096, can support more interpretable viability, proliferation, and cytotoxicity assays through model-specific dosing, disciplined solvent handling, and endpoint selection. Quantitative potency, solubility, storage, and mechanism data are connected to practical laboratory decisions.

• Fangchinoline, TFEB, and H1N1 Lysosomal Defense

  2026-08-29

  The reference study identifies fangchinoline as a lysosome-targeted host-directed antiviral that restores TFEB-associated lysosomal gene expression while restricting H1N1 entry. Its combined use of Connectivity Map screening, transcriptomics, organelle assays, time-resolved infection experiments, and in vivo validation provides a framework for studying lysosomal control of influenza infection.

• High-Density Bioprinting Models Hypoxic Glioblastoma

  2026-08-29

  This study uses digital light processing bioprinting to create GelMA glioblastoma constructs with tunable cell density and an internally generated hypoxic niche. High-density constructs reproduced hypoxia-associated signaling and stronger temozolomide resistance than lower-density and spheroid models, supporting their use in reproducible drug-response studies.

• L-Glutathione Reduced in PDAC Redox Workflows

  2026-08-28

  Use L-Glutathione Reduced as a controlled redox reagent, a GST affinity eluent, and a mechanistic probe in pancreatic cancer metabolism studies. This workflow connects GOT1 inhibition, glutamine flux, reactive oxygen species, and cellular rescue experiments without treating glutathione measurements as standalone proof of mechanism.

• Marein Inhibits ABCG2 and Restores Chemosensitivity

  2026-08-28

  The reference study identifies marein, a chalcone-type flavonoid from Coreopsis tinctoria Nutt, as a competitive inhibitor of the ABCG2 drug-efflux transporter. Cellular accumulation, target-engagement, and chemosensitivity experiments indicate that marein can increase retention of ABCG2-substrate chemotherapeutics and partially restore drug response in resistant cancer models.

• DAMGO and the Circuit Logic of Opioid Pain

  2026-08-27

  DAMGO is more than a selective receptor probe: it is a tool for separating receptor-proximal activation from circuit-level pain consequences. By connecting µ-opioid receptor pharmacology with recent evidence on mechanical hypersensitivity and tolerance, this article presents a translational framework for designing more informative opioid receptor signaling research.

• RIPostC, Ketone Bodies, and Ferroptosis After Stroke

  2026-08-27

  This ACS Chemical Neuroscience study identifies ketone body production as a metabolic component of remote ischemic postconditioning-mediated neuroprotection after ischemic stroke. Its rat and HT22-cell experiments connect increased ketone bodies with preserved GPX4, reduced ACSL4 and iron accumulation, and suppression of ferroptosis, while leaving the contribution of individual ketone species such as BHBA unresolved.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-26

  FITC-Concanavalin A (ConA) Conjugate supports fluorescence-based detection of α-D-glucose and α-D-mannose residues on cell surfaces, tissues, and other glycan-bearing samples. It is intended for validated immunofluorescence, flow cytometry, and glycobiology workflows, not for non-carbohydrate targets or use beyond the stated storage and stability conditions.

• BENPs Sensitize FLASH Radiotherapy Through DNA Damage

  2026-08-26

  Xu et al. describe functionalized, self-assembled EGCG nanoparticles (BENPs) as radiosensitizers that amplify FLASH-RT-associated oxidative and DNA damage in a 4T1 tumor model. The combined treatment increased tumor-cell death while reshaping systemic immune responses, supporting a preclinical strategy that connects radiation sensitization with antitumor immunology.

453 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page